Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OCUL 
Ocular Therapeutix Inc (OCUL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OCUL (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 321.33% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.21B USD | Price to earnings Ratio - | 1Y Target Price 17.45 |
Price to earnings Ratio - | 1Y Target Price 17.45 | ||
Volume (30-day avg) 1599667 | Beta 1.33 | 52 Weeks Range 4.06 - 11.78 | Updated Date 04/1/2025 |
52 Weeks Range 4.06 - 11.78 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate -0.22 | Actual -0.29 |
Profitability
Profit Margin - | Operating Margin (TTM) -296.07% |
Management Effectiveness
Return on Assets (TTM) -30.53% | Return on Equity (TTM) -95.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 847723833 | Price to Sales(TTM) 18.94 |
Enterprise Value 847723833 | Price to Sales(TTM) 18.94 | ||
Enterprise Value to Revenue 13.3 | Enterprise Value to EBITDA -6.06 | Shares Outstanding 159022000 | Shares Floating 124121633 |
Shares Outstanding 159022000 | Shares Floating 124121633 | ||
Percent Insiders 1.01 | Percent Institutions 85.07 |
Analyst Ratings
Rating 4.56 | Target Price 18.22 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ocular Therapeutix Inc
Company Overview
History and Background
Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, MA. It is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel platform technology. Key milestones include FDA approval of DEXTENZA and ongoing clinical trials for pipeline products.
Core Business Areas
- Commercial Products: Focuses on the commercialization and sales of currently approved products like DEXTENZA.
- Research and Development: Dedicated to discovering and developing new therapies for ophthalmic diseases, leveraging the bioresorbable hydrogel platform.
- Manufacturing: Producing the products using the hydrogel platform technology and ensuring product quality and supply.
Leadership and Structure
The leadership team includes key executives in roles such as CEO, CFO, and Chief Medical Officer. The organizational structure includes departments for R&D, commercial operations, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- DEXTENZA: A corticosteroid insert placed in the punctum of the eye to treat ocular inflammation and pain following ophthalmic surgery. Market share data is variable and depends on the specific market segment; however, DEXTENZA is a significant competitor to topical steroid eye drops. Competitors include generic and branded topical steroids such as prednisolone acetate (e.g., Pred Forte, Omnipred) and difluprednate (Durezol). Its 2023 revenue was $54.7 million.
- PAXTRAVA: A resorbable intracanalicular insert containing travoprost used to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Competitors include prostaglandin analogs such as latanoprost, bimatoprost, and tafluprost; Rho kinase inhibitors like netarsudil (Rhopressa); and other IOP-lowering medications or procedures.
Market Dynamics
Industry Overview
The ophthalmic market is characterized by increasing prevalence of eye diseases such as glaucoma, dry eye, and diabetic retinopathy. Technological advancements and growing aging populations are driving market growth.
Positioning
Ocular Therapeutix is positioned as an innovator in drug delivery, offering sustained-release therapies that address compliance issues associated with traditional eye drops. Their competitive advantage lies in their proprietary hydrogel technology.
Total Addressable Market (TAM)
The global ophthalmic market is expected to reach over $45 billion. Ocular Therapeutix is positioned to capture a portion of this market with its innovative drug delivery systems, targeting unmet needs in postoperative inflammation and glaucoma management.
Upturn SWOT Analysis
Strengths
- Proprietary bioresorbable hydrogel platform
- FDA-approved product (DEXTENZA)
- Strong IP portfolio
- Targeted drug delivery technology
Weaknesses
- Limited commercial infrastructure
- Dependence on single product for revenue
- Need for additional financing
- Competition from established pharmaceutical companies
Opportunities
- Expansion of DEXTENZA indications
- Development of new pipeline products
- Partnerships with larger pharmaceutical companies
- Entry into new geographic markets
Threats
- Competition from generic drugs
- Regulatory hurdles
- Clinical trial failures
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- ALC
- VRX
- AGN
Competitive Landscape
Ocular Therapeutix's advantage lies in its sustained-release drug delivery technology. Its disadvantages include its smaller size and limited resources compared to larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by the launch and adoption of DEXTENZA.
Future Projections: Future growth is projected to come from expanded DEXTENZA indications, new product launches, and potential partnerships. Analyst estimates vary but generally project revenue growth over the next few years.
Recent Initiatives: Recent strategic initiatives include expanding the DEXTENZA sales force, advancing pipeline programs in clinical trials, and pursuing partnerships for ex-US commercialization.
Summary
Ocular Therapeutix is a biopharmaceutical company with promising technology but faces challenges in commercialization and competition. DEXTENZA's success is driving revenue, but continued investment in R&D is necessary for future growth. The company needs to expand its product portfolio and secure partnerships to enhance its market position. They face financial risks that require them to raise money through offerings.
Similar Companies
ALC
Alcon AG
ALC
Alcon AG
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change and may not be accurate. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ocular Therapeutix Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2014-07-25 | Executive Chairman, President & CEO Dr. Pravin U. Dugel M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 274 | Website https://www.ocutx.com |
Full time employees 274 | Website https://www.ocutx.com | ||
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.